Top

Obesity Surgery

Published in:

01-10-2020 | Obesity | Original Contributions

Preoperative Chemerin Level Is Predictive of Inflammatory Status 1 Year After Bariatric Surgery

Authors: Youenn Jouan, Hélène Blasco, Alice Bongrani, Charles Couet, Joëlle Dupont, François Maillot

Published in: Obesity Surgery | Issue 10/2020

Abstract

Background

Obesity is associated with chronic low-grade inflammation, which has been linked to increased morbidity. However, inflammation variably and unpredictably improves after bariatric surgery. This study aimed at (1) evaluating the relationship between amplitude of weight loss and variation of inflammatory parameters after bariatric surgery, and (2) identifying, among clinical and biological baseline parameters, predictive factors of variation in inflammatory parameters.

Methods

In a prospective cohort of patients who underwent bariatric surgery, serum concentrations of interleukin (IL)-6, IL-10, resistin, leptin, adiponectin chemerin, and C-reactive protein (CRP) were measured preoperatively and 1 year after surgery, and routine clinical and biochemical parameters were retrieved. Univariate and multivariate analyses (partial least square method) were performed to assess how parameters were associated with weight loss and to predict improvement of inflammatory parameters.

Results

Eighty-seven patients were included (mean weight ± SD 136.3 ± 3.2 kg, 35 gastric bypasses, 52 sleeve gastrectomies). In parallel with weight loss (39.5 ± 13.8 kg), pro-inflammatory markers (IL-6, CRP, leptin, resistin) significantly decreased, and anti-inflammatory markers (IL-10, adiponectin) increased. Multivariate analysis revealed a significant association between weight loss and improvement in inflammatory parameters. Among all the clinical and biological preoperative parameters, baseline chemerin level was the only parameter that was significantly associated with global improvement of the inflammatory status after surgery.

Conclusion

The amplitude of weight loss 1 year after bariatric surgery was strongly correlated with improvement of inflammatory profile, which could be predicted by baseline plasma level of chemerin. This suggests a key role of chemerin in obesity-driven inflammation, and a potential use as a biomarker.

Available only for authorised users

Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. Elsevier. 2014;384(9945):766–81

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet Elsevier. 2005;365(9468):1415–28.PubMed

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.PubMed

de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc Cambridge University Press. 2012;71(02):332–8.PubMed

Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, et al. Obesity and Inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. Hindawi Publishing Corporation. 2013;2013(10):1–11.

Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5.PubMed

Park H, Park Y, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-a and IL-6. Diabetes Res Clin Pract. 2005;69:1–7.

Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. Nature Publishing Group. 2014;14(7):463–77.PubMed

Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017;13(6):368–80.PubMed

10.

Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. Nature Publishing Group. 2008;454(7203):436–44.PubMed

11.

Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2015;16(1):22–34.

12.

Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9.PubMed

13.

Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016;12(1):15–28.PubMed

14.

Brestoff JR, Artis D. Immune regulation of metabolic homeostasis in health and disease. Cell. Elsevier. 2015;161(1):146–60.PubMedPubMedCentral

15.

Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.PubMedPubMedCentral

16.

Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie. 2012;94(10):2137–42.PubMed

17.

Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. BioScientifica. 2014;220(2):T47–59.PubMedPubMedCentral

18.

Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. Elsevier Ltd. 2010;21(11):660–7.PubMed

19.

Helfer G, Wu Q-F. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. Bioscientifica Ltd. 2018;238(2):R79–94.PubMedPubMedCentral

20.

Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2012;14(3):245–62.PubMed

21.

Chang S-S, Eisenberg D, Zhao L, et al. Chemerin activation in human obesity. Obesity. 2016;24(7):1522–9.PubMed

22.

Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. Villa E, editor. PLoS ONE. Public Library of Science; 2014;9(12):e113915–14.

23.

Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. In: Colquitt JL, editor. Cochrane Database Syst Rev, vol. 8. Chichester: John Wiley & Sons, Ltd; 2014. p. CD003641.

24.

Picot J, Jones J, Colquitt JL, et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess. 2009;13(41):1. –190–215–357–iii–ivPubMed

25.

Frikke-Schmidt H, O’Rourke RW, Lumeng CN, et al. Does bariatric surgery improve adipose tissue function? Obes Rev. 2016;17(9):795–809

26.

Goktas Z, Moustaid-Moussa N, Shen C-L, et al. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol. Frontiers. 2013;4:69.

27.

Sauerland S, Angrisani L, Belachew M, et al. Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surgical endoscopy. 2005;19(2):200–21

28.

Laville M, Romon M, Chavrier G, et al. Recommendations regarding obesity surgery. Obes Surg. Springer-Verlag. 2005;15(10):1476–80.PubMed

29.

Haute Autorité de Santé. Obésité: prise en charge chirurgicale de l’adulte [Internet]. 2009. Available from: http://www.has-sante.fr

30.

Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10.PubMed

31.

Iacobini C, Pugliese G, Fantauzzi CB, et al. Metabolically healthy versus metabolically unhealthy obesity. Metabolism Elsevier Inc. 2019;92(C):51–60.PubMed

32.

Arismendi E, Rivas E, Agustí A, Ríos J, Barreiro E, Vidal J, et al. The systemic inflammome of severe obesity before and after bariatric surgery. Thatcher TH, editor. PLoS ONE. Public Library of Science; 2014;9(9):e107859.

33.

Iannelli A, Anty R, Schneck AS, et al. Evolution of low-grade systemic inflammation, insulin resistance, anthropometrics, resting energy expenditure and metabolic syndrome after bariatric surgery: a comparative study between gastric bypass and sleeve gastrectomy. J Visc Surg. Elsevier Masson SAS. 2013;150(4):269–75.PubMed

34.

Gumbau V, Bruna M, Canelles E, et al. A prospective study on inflammatory parameters in obese patients after sleeve gastrectomy. Obes Surg. Springer US. 2014;24(6):903–8.PubMed

35.

Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-α stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis. Elsevier Inc. 2013;9(2):306–14.PubMed

36.

Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis. Elsevier Inc. 2011;7(5):618–24.PubMedPubMedCentral

37.

Netto BDM, Bettini SC, Clemente APG, et al. Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg. 2014;25(6):1010–8.

38.

Dalmas E, Rouault C, Abdennour M, et al. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr. American Society for Nutrition. 2011;94(2):450–8.PubMed

39.

Vilarrasa N, Vendrell J, Sánchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol. Blackwell Publishing Ltd. 2007;67(5):679–86.

40.

Morínigo R, Casamitjana R, Delgado S, et al. Insulin resistance, inflammation, and the metabolic syndrome following Roux-en-Y gastric bypass surgery in severely obese subjects. Diabetes Care. American Diabetes Association. 2007;30(7):1906–8.PubMed

41.

Marantos G, Daskalakis M, Karkavitsas N, et al. Changes in metabolic profile and adipoinsular axis in morbidly obese premenopausal females treated with restrictive bariatric surgery. World J Surg. 2011;35(9):2022–30.PubMed

42.

Ress C, Tschoner A, Engl J, et al. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Investig. Wiley/Blackwell (10.1111). 2010;40(3):277–80.

43.

Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2010;95(6):2892–6.PubMed

44.

Terra X, Auguet T, Guiu-Jurado E, et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. Springer US. 2013;23(11):1790–8.PubMed

45.

Freitas WR, Oliveira LVF, Perez EA, et al. Systemic inflammation in severe obese patients undergoing surgery for obesity and weight-related diseases. Obes Surg Obesity Surgery. 2018;307(5):1–12.

46.

Debnath M, Agrawal S, Agrawal A, et al. Metaflammatory responses during obesity: pathomechanism and treatment. Obes Res Clin Pract. Asia Oceania Association for the Study of Obesity. 2015;10(2):1–11.

47.

Parlee SD, Ernst MC, Muruganandan S, et al. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-α. Endocrinology. 2010;151(6):2590–602.PubMed

48.

Bondue B, Wittamer V, Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. Elsevier Ltd. 2011;22(5-6):331–8.PubMed

49.

Mattern A, Zellmann T, Beck-Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life. 2014;66(1):19–26.PubMed

50.

Chakaroun R, Raschpichler M, Klöting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism. 2012;61(5):706–14.PubMed

51.

Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediat Inflamm. Hindawi. 2014;2014(4):425068–11.

52.

Bai F, Zheng W, Dong Y, et al. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget. 2018;9(1):1266–78.PubMed

53.

Buechler C. Chemerin, a novel player in inflammatory bowel disease. Cell Mol Immunol. Nature Publishing Group. 2014;11(4):315–6.PubMedPubMedCentral

Title: Preoperative Chemerin Level Is Predictive of Inflammatory Status 1 Year After Bariatric Surgery
Authors: Youenn Jouan
Hélène Blasco
Alice Bongrani
Charles Couet
Joëlle Dupont
François Maillot
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Obesity
Obesity
Bariatric Surgery
Bariatric Surgery
Cytokines
Published in: Obesity Surgery / Issue 10/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-020-04584-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Preoperative Chemerin Level Is Predictive of Inflammatory Status 1 Year After Bariatric Surgery

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

Laparoscopic Management of Internal Hernia After One Anastomosis Gastric Bypass (OAGB)

Factors Associated with the Development of Anemia During Pregnancy After Sleeve Gastrectomy

Stapling Through a Bougie During Sleeve Gastrectomy in a Superobese Patient—a Video Vignette

Necrosis of the Nissen-Sleeve Gastrectomy (N-SG) Wrap

The Preoperative Dietary Inflammatory Index Predicts Changes in Cardiometabolic Risk Factors After 12 Months of Roux-en-Y Gastric Bypass

Vertebral Artery Dissection After Sleeve Gastrectomy: a Case Report